2 Stocks That Could Soar This Year
Source: Motley Fool
2026-01-31 19:13:00 ET
In the volatile biotech industry, companies can see their shares soar over relatively short periods on strong clinical progress for exciting pipeline candidates.
That's precisely what could happen to Exelixis (NASDAQ: EXEL) and Summit Therapeutics (NASDAQ: SMMT) this year. And the even better news is that there are reasons to consider holding onto these drugmakers' shares even beyond the next 12 months. Let's find out more.
Image source: Getty Images.
Exelixis Inc.
NASDAQ: EXEL
EXEL Trading
-1.16% G/L:
$40.83 Last:
660,350 Volume:
$41.57 Open:
EXEL Latest News
February 28, 2026 04:57:00 am
3 Reasons Exelixis Stock Could Deliver Market?Beating Returns Over the Next Decade
February 24, 2026 04:05:00 pm
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
February 24, 2026 10:58:00 am
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
February 20, 2026 04:05:00 pm
Exelixis: The Cash?Generating Biotech That I Think Deserves a Closer Look in 2026
EXEL Stock Data
$11,614,618,641
260,551,394
1.54%
313
N/A
Biotechnology & Life Sciences
Healthcare
US
Alameda
